KOSDAQBiotech & Pharma028300

HLB

₩27,350▼ 3.36%2026-11-18 close
Market Cap
₩3.6T
Turnover
₩13B
Volume
470K
Shares out.
130M
PER
—
PBR
12.6×
EPS
-₩1,194
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Liver cancer drug under FDA re-review as losses persist

HLB faces an FDA review target date of April 9, 2027 for its rivoceranib and camrelizumab combination in liver cancer, while operating losses have continued for five straight quarters on a disclosed basis through Q3 2026.

  1. 1

    The combination NDA for rivoceranib and camrelizumab was resubmitted on October 9, 2026. The FDA classified it as Class 2 and set a review target date of April 9, 2027.

  2. 2

    Revenue reached KRW 84.2 billion in 2025, up 23.6% from the prior year and rising for two straight years from 2024, while the operating loss stood at KRW 104.2 billion, the fourth consecutive annual loss.

  3. 3

    The net loss attributable to controlling shareholders widened to KRW 220.5 billion in 2025 from KRW 92 billion in 2024, and operating cash flow was negative KRW 92.6 billion in the same year.

  4. 4

    Q3 2026 revenue was KRW 26 billion, up 17.5% year on year. The operating loss was KRW 27.5 billion, and the net loss attributable to controlling shareholders was KRW 18.1 billion, narrower than a year earlier.

  5. 5

    The debt-to-equity ratio rose to 88.1% at the end of 2025 from 36.1% in 2024, and total equity stood at KRW 494.4 billion.

02

Business structure

HLB's business is organized around its anticancer drug pipeline. The core asset is the combination of rivoceranib and the anti-PD-1 antibody camrelizumab as a first-line treatment for unresectable hepatocellular carcinoma.

Its U.S. subsidiary Elevar Therapeutics handles the U.S. approval process, while the Chinese partner Hengrui is responsible for camrelizumab and for manufacturing-related parts of the program.

The second pillar is lirafugratinib for cholangiocarcinoma, which a 2026 report said received FDA approval in September 2026, with a U.S. launch planned for Q4 2026 and broader overseas expansion in preparation.

The combination was included as a first-line option for advanced hepatocellular carcinoma in the 2025 BCLC and ESMO guidelines, based on the global Phase 3 CARES-310 trial.

Competition centers on existing immunotherapy combinations, and the clinical data is already published, so the debate has shifted toward manufacturing and quality requirements. Within the HLB group, Chairman Kim Tae-han oversees the bio division, and Kim Hong-cheol serves as HLB's CEO.

Revenue remains in an early commercialization stage, so operating expenses weigh heavily relative to annual sales.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩22.1B-₩23B−104.1%
2025Q4₩28.7B-₩29.4B−102.5%
2026Q1₩18.7B-₩23.2B−124.1%
2026Q2₩28B-₩22.5B−80.4%
2026Q3₩26B-₩27.5B−105.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩179.7B-₩74.7B-₩78.2B−41.5%−12.3%38.4%
2023₩42.9B-₩125B-₩189.1B−291.4%−36.1%29.1%
2024₩68.1B-₩118.5B-₩92B−174.0%−16.0%36.1%
2025₩84.2B-₩104.2B-₩220.5B−123.8%−52.7%88.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

On a disclosed annual basis, revenue fell from KRW 179.7 billion in 2022 to KRW 42.9 billion in 2023, a 76.1% decline.

It then rose to KRW 68.1 billion in 2024, up 58.8%, and to KRW 84.2 billion in 2025, up 23.6%, marking two straight years of growth from 2024. 2022 was the largest revenue year in the 2022–2025 period, and 2023 was the smallest.

The operating loss was KRW 74.7 billion in 2022, KRW 125 billion in 2023, KRW 118.5 billion in 2024 and KRW 104.2 billion in 2025, a loss in each of the four years. The operating margin worsened from -41.5% in 2022 to -291.4% in 2023, then improved to -174.0% in 2024 and -123.8% in 2025, as revenue grew.

The net loss attributable to controlling shareholders was KRW 78.2 billion in 2022, KRW 189.1 billion in 2023, KRW 92 billion in 2024 and KRW 220.5 billion in 2025. In 2025 that loss widened even though the operating loss narrowed, so the two measures moved in opposite directions.

Net loss including non-controlling interests was KRW 235.4 billion in 2025, a separate figure from the controlling-shareholder number.

Operating cash flow was negative in all four years: negative KRW 61.8 billion in 2022, negative KRW 111.6 billion in 2023, negative KRW 114.3 billion in 2024 and negative KRW 92.6 billion in 2025. The debt-to-equity ratio rose from 36.1% in 2024 to 88.1% in 2025.

At the end of 2025, total liabilities were KRW 435.8 billion and total equity was KRW 494.4 billion, of which KRW 418.5 billion belonged to controlling shareholders.

Quarterly revenue was KRW 22.1 billion in Q3 2025, KRW 28.7 billion in Q4 2025, KRW 18.7 billion in Q1 2026, KRW 28 billion in Q2 2026 and KRW 26 billion in Q3 2026.

The operating loss ran for five straight quarters, from KRW 23 billion in Q3 2025 to KRW 29.4 billion in Q4 2025, KRW 23.2 billion in Q1 2026, KRW 22.5 billion in Q2 2026 and KRW 27.5 billion in Q3 2026. The net loss attributable to controlling shareholders over the last four quarters totaled KRW 158.5 billion.

05

Industry analysis

The liver cancer drug market is expanding. In its 2026 quarterly report, HLB projected the global market to grow from about USD 3.7 billion in 2024 to about USD 9.8 billion by 2030. Because this figure comes from company material, it is best read as a reference rather than an independent forecast.

Advanced hepatocellular carcinoma is typically treated with systemic therapy once surgery is not possible, and the rivoceranib combination competes with existing immunotherapy-based combinations in that first-line setting.

Among Korean biopharma companies, Hugel's botulinum toxin product Letybo received final FDA approval on its third attempt after two complete response letters, a precedent that is often compared with HLB's resubmissions.

Other listed peers in the sector, including Celltrion, Alteogen, SK biopharmaceuticals and Yuhan, each have their own pipelines and overseas approval paths, so regulatory speed and commercial capability serve as the sector comparison points.

HLB's strengths are Phase 3 data and guideline inclusion, while manufacturing quality remains the main variable determining approval.

06

Outlook

The next regulatory step is the FDA's full review. Elevar Therapeutics resubmitted the rivoceranib NDA on October 9, 2026, and the FDA classified it as Class 2 with a target date of April 9, 2027.

Hengrui resubmitted the camrelizumab biologics application on the same day, and the FDA is reviewing the two applications together as a combination.

On the manufacturing side, the rivoceranib drug substance facility received a voluntary action indicated (VAI) classification in July 2026, and the finished-product facility received the same classification in October 2026. The FDA has said it can still conduct additional inspections of the facilities when needed.

A decision before the target date remains possible. Lirafugratinib is scheduled for a U.S. launch in Q4 2026, and expansion of its indications is being pursued. Company announcements indicate that topline results and CAR-T clinical data from group affiliates are expected to follow from the end of 2026.

These milestones could change the revenue and loss profile, and their effect on reported results will show up in quarterly reports after launch.

07

Valuation

PER
—
PBR
12.6×
ROE
-46.1%
EPS
-₩1,194
BPS
₩2,330
Dividend per share
₩0

Valuation is hard to read through earnings-based multiples. Because the company has posted net losses over the last four quarters, its price-to-earnings ratio cannot be calculated.

The price-to-book ratio sits in a range with a large premium over net assets, which suggests the share price reflects expectations about pipeline outcomes more than the asset base. This is an interpretation of what the market is pricing in, not a view on the direction of the share price.

Because the share price may move with the realization of those expectations, the FDA review outcome is a central variable. Dividend payouts are effectively absent, so earnings recovery and funding arrangements are the key points to watch for shareholder returns.

The rise in the debt-to-equity ratio to 88.1% at the end of 2025 is also a fact to weigh on financial burden.

Compared with other listed companies in the sector, multiples vary widely with pipeline stage and approval progress, so reviewing each pipeline's regulatory timeline gives a more accurate picture than a simple multiple comparison.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

Phase 3 data and guideline inclusion

The CARES-310 Phase 3 trial reportedly showed a 36% lower risk of death versus sorafenib and a median overall survival of 23.8 months for the combination. On that basis, it was included as a first-line option for advanced hepatocellular carcinoma in the 2025 BCLC and ESMO guidelines before approval. The clinical efficacy has already been reviewed by academic societies and guidelines.

Full FDA review and target date

The FDA classified the resubmission as Class 2 and set a target date of April 9, 2027. Both facilities have received VAI classifications, which the company presents as evidence that the earlier manufacturing issues have been resolved. A decision before the target date remains possible.

Revenue growth and margin improvement

Revenue rose to KRW 68.1 billion in 2024 and KRW 84.2 billion in 2025, two straight years of growth, and Q3 2026 revenue was up 17.5% year on year. The operating margin improved from -291.4% in 2023 to -123.8% in 2025. The planned Q4 2026 U.S. launch of lirafugratinib is the next checkpoint for revenue expansion.

09

Bear factors

Repeated FDA rejections and manufacturing issues

HLB first filed in May 2023 but received complete response letters in May 2024, March 2025 and July 2026. Most of the rejections centered on manufacturing facility findings rather than clinical efficacy.

Whether the manufacturing and quality data meet approval standards remains the central issue, and the timeline could still slip beyond April 2027.

Persistent operating losses and cash outflows

The operating loss has continued for four straight years from 2022 to 2025 and for five straight quarters through Q3 2026. Operating cash flow was negative in all four years, with KRW 92.6 billion of outflow in 2025.

Rising debt and wider controlling-shareholder losses

The debt-to-equity ratio rose from 36.1% in 2024 to 88.1% in 2025, and total liabilities at the end of 2025 were KRW 435.8 billion. The net loss attributable to controlling shareholders widened to KRW 220.5 billion in 2025 from a year earlier.

The fact that this loss grew in a year when the operating loss narrowed is a reason to examine the full loss structure.

10

Risk factors

Regulatory risk

If manufacturing requirements are not met in the FDA review, approval could be delayed again. Rivoceranib production relies on the facilities of the partner Hengrui, and the FDA has said it can conduct further inspections when needed. The partner's pace of response remains a variable for the timeline.

Financial risk

Operating cash flow has been negative for four straight years, and the debt-to-equity ratio rose to 88.1% in 2025. Of total equity of KRW 494.4 billion, KRW 418.5 billion belongs to controlling shareholders.

Any additional funding could bring dilution or higher debt, so cash flow improvement is a point to keep monitoring.

Pipeline concentration risk

Revenue expectations are concentrated in two products, the liver cancer and bile duct cancer drugs. If the U.S. launch of lirafugratinib is delayed or its indication expansion slips, diversification of the revenue base would slow. The outcome of one or two pipeline programs could materially affect the overall value of the company.

11

What to watch next

  1. Q4 2026

    The U.S. launch of lirafugratinib, a cholangiocarcinoma treatment, is scheduled for Q4 2026. The next checkpoint is the revenue contribution and operating loss trend in quarterly reports after launch.

  2. After year-end 2026

    Topline results from group pipeline programs and CAR-T clinical data are reported to follow from the end of 2026. It will be important to see how the results shape the assessment of follow-on pipeline programs.

  3. End of March 2027

    The 2026 annual report is due by the end of March 2027. It will provide confirmed full-year revenue, operating loss, net loss attributable to controlling shareholders and cash flow, serving as the baseline for comparing 2026 with 2025.

  4. April 9, 2027

    This is the FDA review target date for the rivoceranib and camrelizumab combination. The approval decision is expected around this date, although a decision before the target date remains possible.

12

Overall view

The central question for HLB is whether the FDA approves the rivoceranib and camrelizumab combination for liver cancer. The resubmitted application was classified as Class 2, with a target date of April 9, 2027, and the manufacturing facilities have completed inspections with VAI classifications.

The Phase 3 data and guideline inclusion are supporting factors, but three prior rejections show that manufacturing quality is the decisive hurdle. On a disclosed basis, revenue has grown for two straight years since 2024, and the operating margin improved from -291.4% in 2023 to -123.8% in 2025.

On the other side, the operating loss has persisted for four straight years and five straight quarters, and the net loss attributable to controlling shareholders widened to KRW 220.5 billion in 2025. The debt-to-equity ratio rose to 88.1% in 2025, and operating cash flow was negative in all four years.

Q3 2026 losses narrowed from a year earlier, but the net loss attributable to controlling shareholders over the last four quarters totaled KRW 158.5 billion. The next checkpoints are the U.S. launch of lirafugratinib in Q4 2026 and the FDA decision around April 9, 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. hankyung.com
  2. leadeconomy.co.kr
  3. hitnews.co.kr
  4. news.mtn.co.kr
  5. newsis.com
  6. dailian.co.kr
  7. news.jkn.co.kr
  8. finance-scope.com
  9. make2t.kr
  10. asiatoday.co.kr
  11. newsway.co.kr
  12. fntimes.com
  13. ittimes.com
  14. medicopharma.co.kr
  15. kr.investing.com
  16. m.sedaily.com
  17. kpenews.com
  18. ncbi.nlm.nih.gov

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis